284 related articles for article (PubMed ID: 12913106)
1. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
Kattan MW; Shariat SF; Andrews B; Zhu K; Canto E; Matsumoto K; Muramoto M; Scardino PT; Ohori M; Wheeler TM; Slawin KM
J Clin Oncol; 2003 Oct; 21(19):3573-9. PubMed ID: 12913106
[TBL] [Abstract][Full Text] [Related]
2. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy.
Shariat SF; Walz J; Roehrborn CG; Montorsi F; Jeldres C; Saad F; Karakiewicz PI
J Urol; 2008 Apr; 179(4):1593-7. PubMed ID: 18295256
[TBL] [Abstract][Full Text] [Related]
3. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
Shariat SF; Walz J; Roehrborn CG; Zlotta AR; Perrotte P; Suardi N; Saad F; Karakiewicz PI
J Clin Oncol; 2008 Mar; 26(9):1526-31. PubMed ID: 18349404
[TBL] [Abstract][Full Text] [Related]
4. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597
[TBL] [Abstract][Full Text] [Related]
5. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
[TBL] [Abstract][Full Text] [Related]
6. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
[TBL] [Abstract][Full Text] [Related]
7. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.
Sinnreich O; Kratzsch J; Reichenbach A; Gläser C; Huse K; Birkenmeier G
Prostate; 2004 Nov; 61(3):201-8. PubMed ID: 15368477
[TBL] [Abstract][Full Text] [Related]
9. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
[TBL] [Abstract][Full Text] [Related]
10. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
[TBL] [Abstract][Full Text] [Related]
11. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
12. Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.
Rouprêt M; Hupertan V; Comperat E; Drouin SJ; Phé V; Xylinas E; Demanse D; Sibony M; Richard F; Cussenot O
BJU Int; 2009 Sep; 104(6):813-7; discussion 817-8. PubMed ID: 19254280
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta as a clinical biomarker for prostate cancer.
Perry KT; Anthony CT; Case T; Steiner MS
Urology; 1997 Jan; 49(1):151-5. PubMed ID: 9000208
[TBL] [Abstract][Full Text] [Related]
14. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
[TBL] [Abstract][Full Text] [Related]
15. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.
Shariat SF; Bensalah K; Karam JA; Roehrborn CG; Gallina A; Lotan Y; Slawin KM; Karakiewicz PI
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5377-84. PubMed ID: 17875766
[TBL] [Abstract][Full Text] [Related]
16. Development and internal validation of a nomogram predicting extracapsular extension in radical prostatectomy specimens.
Satake N; Ohori M; Yu C; Kattan MW; Ohno Y; Miyakawa A; Hatano T; Tachibana M
Int J Urol; 2010 Mar; 17(3):267-72. PubMed ID: 20132361
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
[TBL] [Abstract][Full Text] [Related]
18. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
Graefen M; Ohori M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Erbersdobler A; Henke RP; Huland H; Wheeler TM; Slawin K; Scardino PT; Kattan MW
J Urol; 2004 Jan; 171(1):200-3. PubMed ID: 14665876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
